eContouring for Head and Neck
This session will include an introduction covering common head and neck cancer subtypes. Basics of head and neck anatomy will be reviewed. Subsequently, we will transition to a case-based approach that will demonstrate target volume design for common head and neck tumor types.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand patterns of spread based on primary tumor location and develop appropriate CTVs to target potential microscopic disease.
- Translate pathological findings into adjuvant target volumes in post-operative cases.
- Develop dose painting strategies for common cases of head and neck cancer.
Faculty:
A list of all meeting faculty and Individual presenter disclosures can be found on the Schedule of Events page.
Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee webpage.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.